Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

News

 

Netherlands to end free choice in health care

The Dutch government is seeking to end free choice within health care by removing the obligation on health insurers to reimburse care from any provider. The proposal is part of the cabinet’s plan to shake up the Netherland’s health care system, and will make it much harder for new entrants to compete with established providers. HBI chats with two market experts to find out more.

KKR exits Max Healthcare

US private equity player KKR has solid its entire stake in India-based hospital chain Max Healthcare, marking its exit from the group, for around Rs9,200 crore. The deal marks its largest exit from an Indian firm, and is the largest single block deal done by any PE firm in India.

Lusiadas deal still on as seller carries cost of muti-million fine

The planned acquisition of Lusiadas Saude, Portugal's third largest hospital group, by France's third largest hospital group Vivalto Sante, will not be impacted by the €34.2m fine that has been handed to Lusiadas by Portugal's competition authority.

KKR may switch to private credit to finance IVI RMA takeover

Facing an increasingly volatile market, American buyout / investment firm KKR may switch to direct lenders to finance its acquisition of fertility company IVI RMA Global, despite agreeing €800m of underwritten financing from four investment banks.

Four Seasons seller happy to split group for sale

Potential buyers of Four Seasons Health Care Group’s (FSHC) 110 homes must place their bids before the end of September, insists Christie & Co, the business broker in charge of the sale.

Ramsay deal at risk due to French connection

The US$15bn KKR acquisition of Australia-based Ramsay may not go ahead, owing to consistent problems with the hospital group’s French subsidiary. HBI chats to an Australian analyst to find out more.

Synlab still benefiting from Covid testing windfall

Europe’s largest lab group Synlab earned €618m from Covid testing in the first half of 2022. This was a 30% drop from H1 2021, but higher than what it had initially forecasted for the period. Revenue from underlying, non-Covid activity was strong, at 7.2%, helped by several bolt-on acquisitions.

Find Us